Address
AGILeBiotics B.V.
De Mudden 14
9747AW Groningen
the Netherlands
Contact
Dr. Andreas A. Bastian+31(0)639607999
a.a.bastian@agilebiotics.com
Website
Toframicin; The next-generation antibiotic
The next-generation aminoglycoside antibiotic
Toframicin is a semi-synthetic antibiotic which is in development for the treatment of hospital-acquired-/ventilator-associated pneumonia, bloodstream infections and neonatal sepsis.
Toframicin has ultra-broad spectrum activity, overcome drug class-related bacterial resistance, and offers an increased therapeutic window.
Technology:
Microorganisms:
Application:
Development stage:
- Antimicrobial compounds
- Infection prevention
- Antimicrobial stewardship
- Microbial diagnostics
- Antimicrobial compound/strategy
- Removal antibiotics/bacteria
Microorganisms:
- Bacteria
- Viruses
- Fungi
- Yeasts
- Parasites
Application:
- Human
- Veterinary
- AgriFood
- Environmental
- Other
Development stage:
- Development
- Research
- Validation
- Market entry
- Marketed product
Organization:
Partnering:
Funding organisation:
Infectious disease area:
Geographic origin:
- Company
- Academia
- Institute
- NGO
- Government
Partnering:
- License
- Co-develop
- Outsource
- Joint Venture
- Sell
Funding organisation:
Infectious disease area:
Geographic origin:
Multi-asset pharmaceutical companies focusing on anti-infective development.
AGILeBiotics B.V. is a pre-clinical stage biotech company focusing on the development of novel antibiotics
In addition, we are interested in developing Toframicin against MDR tuberculosis and lung infections associated with Cystic Fibrosis.
